CA3169791A1 - Compounds for use in the treatment of coronavirus infection - Google Patents
Compounds for use in the treatment of coronavirus infection Download PDFInfo
- Publication number
- CA3169791A1 CA3169791A1 CA3169791A CA3169791A CA3169791A1 CA 3169791 A1 CA3169791 A1 CA 3169791A1 CA 3169791 A CA3169791 A CA 3169791A CA 3169791 A CA3169791 A CA 3169791A CA 3169791 A1 CA3169791 A1 CA 3169791A1
- Authority
- CA
- Canada
- Prior art keywords
- day
- compound
- use according
- days
- cov
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382152.5 | 2020-03-02 | ||
| EP20382152 | 2020-03-02 | ||
| EP20382192.1 | 2020-03-13 | ||
| EP20382192 | 2020-03-13 | ||
| EP20382266 | 2020-04-02 | ||
| EP20382266.3 | 2020-04-02 | ||
| EP20382339 | 2020-04-27 | ||
| EP20382339.8 | 2020-04-27 | ||
| EP20382816.5 | 2020-09-16 | ||
| EP20382816 | 2020-09-16 | ||
| EP20382815.7 | 2020-09-16 | ||
| EP20382815 | 2020-09-16 | ||
| PCT/EP2021/055137 WO2021175826A1 (en) | 2020-03-02 | 2021-03-02 | Compounds for use in the treatment of coronavirus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3169791A1 true CA3169791A1 (en) | 2021-09-10 |
Family
ID=74797953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3169791A Pending CA3169791A1 (en) | 2020-03-02 | 2021-03-02 | Compounds for use in the treatment of coronavirus infection |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230158102A1 (https=) |
| EP (1) | EP4114436A1 (https=) |
| JP (1) | JP2023517295A (https=) |
| KR (1) | KR20220151181A (https=) |
| CN (1) | CN115666615A (https=) |
| AU (1) | AU2021232534A1 (https=) |
| BR (1) | BR112022017008A2 (https=) |
| CA (1) | CA3169791A1 (https=) |
| CL (1) | CL2022002398A1 (https=) |
| CO (1) | CO2022014115A2 (https=) |
| IL (1) | IL296066A (https=) |
| MX (1) | MX2022010922A (https=) |
| PE (1) | PE20231069A1 (https=) |
| PY (1) | PY2117315A (https=) |
| TW (1) | TW202144380A (https=) |
| UY (1) | UY39108A (https=) |
| WO (1) | WO2021175826A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021231521A1 (en) * | 2020-03-02 | 2022-10-06 | Pharma Mar, S.A. | PLD for use in combination in the treatment of coronavirus |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8922026D0 (en) * | 1989-09-29 | 1989-11-15 | Pharma Mar Sa | Novel anti-viral and cytotoxic agent |
| GB9803448D0 (en) | 1998-02-18 | 1998-04-15 | Pharma Mar Sa | Pharmaceutical formulation |
| CA2405779A1 (en) | 2000-04-07 | 2001-10-18 | The Trustees Of The University Of Pennsylvania | Tamandarin and didemnin analogs and methods of making and using them |
| UA76718C2 (uk) | 2000-06-30 | 2006-09-15 | Фарма Мар, С.А. | Протипухлинні похідні аплідину |
| JP2006523214A (ja) | 2003-03-21 | 2006-10-12 | ジユーリー，マデレーン・エム | タマンダリン類似物およびこれらのフラグメントそして製造方法および使用方法 |
| US7605135B2 (en) * | 2003-11-10 | 2009-10-20 | The University Of Hong Kong | Baicalin as a treatment for SARS infection |
| JP2012512839A (ja) * | 2008-12-19 | 2012-06-07 | ファルマ、マール、ソシエダード、アノニマ | 抗腫瘍性化合物 |
| WO2011020913A2 (en) | 2009-08-21 | 2011-02-24 | Pharma Mar, S.A. | Cyclodepsipeptide antiviral compounds |
| CN115461067A (zh) * | 2020-03-02 | 2022-12-09 | 法马马有限公司 | 用于炎症的化合物 |
-
2021
- 2021-03-02 US US17/908,524 patent/US20230158102A1/en active Pending
- 2021-03-02 CA CA3169791A patent/CA3169791A1/en active Pending
- 2021-03-02 TW TW110107291A patent/TW202144380A/zh unknown
- 2021-03-02 CN CN202180018709.2A patent/CN115666615A/zh active Pending
- 2021-03-02 KR KR1020227034222A patent/KR20220151181A/ko active Pending
- 2021-03-02 PE PE2022001871A patent/PE20231069A1/es unknown
- 2021-03-02 JP JP2022552932A patent/JP2023517295A/ja active Pending
- 2021-03-02 BR BR112022017008A patent/BR112022017008A2/pt unknown
- 2021-03-02 AU AU2021232534A patent/AU2021232534A1/en active Pending
- 2021-03-02 WO PCT/EP2021/055137 patent/WO2021175826A1/en not_active Ceased
- 2021-03-02 UY UY0001039108A patent/UY39108A/es unknown
- 2021-03-02 PY PY202102117315A patent/PY2117315A/es unknown
- 2021-03-02 MX MX2022010922A patent/MX2022010922A/es unknown
- 2021-03-02 IL IL296066A patent/IL296066A/en unknown
- 2021-03-02 EP EP21708649.5A patent/EP4114436A1/en active Pending
-
2022
- 2022-09-02 CL CL2022002398A patent/CL2022002398A1/es unknown
- 2022-09-30 CO CONC2022/0014115A patent/CO2022014115A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220151181A (ko) | 2022-11-14 |
| UY39108A (es) | 2021-09-30 |
| JP2023517295A (ja) | 2023-04-25 |
| CN115666615A (zh) | 2023-01-31 |
| PY2117315A (es) | 2022-05-10 |
| MX2022010922A (es) | 2022-09-29 |
| PE20231069A1 (es) | 2023-07-17 |
| AU2021232534A1 (en) | 2022-10-06 |
| TW202144380A (zh) | 2021-12-01 |
| US20230158102A1 (en) | 2023-05-25 |
| BR112022017008A2 (pt) | 2022-10-11 |
| CO2022014115A2 (es) | 2022-11-18 |
| IL296066A (en) | 2022-11-01 |
| CL2022002398A1 (es) | 2023-06-30 |
| EP4114436A1 (en) | 2023-01-11 |
| WO2021175826A1 (en) | 2021-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kaddoura et al. | COVID-19 therapeutic options under investigation | |
| Santos et al. | Antivirals against coronaviruses: candidate drugs for SARS-CoV-2 treatment? | |
| Ashour et al. | A systematic review of the global intervention for SARS-CoV-2 combating: from drugs repurposing to molnupiravir approval | |
| CN110035767B (zh) | 用于治疗与冠状病毒相关的感染的抗病毒组合物 | |
| Wu et al. | Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles | |
| US20230295236A1 (en) | Compounds for use in inflammatory conditions | |
| TWI750051B (zh) | 用於預防或治療嚴重急性呼吸綜合症冠狀病毒２感染疾病的組合物 | |
| KR20200131784A (ko) | 제2형 중증급성호흡기증후군 코로나바이러스 감염 질환의 예방 또는 치료용 조성물 | |
| KR20220150348A (ko) | 코로나바이러스의 치료에 조합하여 사용하기 위한 pld | |
| CA3169791A1 (en) | Compounds for use in the treatment of coronavirus infection | |
| Mina et al. | Potential drug candidates underway several registered clinical trials for battling COVID-19 | |
| KR20230021009A (ko) | 항바이러스 치료로서의 아젤라스틴 | |
| EA050340B1 (ru) | Соединения для применения в лечении коронавирусной инфекции | |
| Fan et al. | Pharmaceutical approaches for COVID-19: An update on current therapeutic opportunities | |
| Sodum et al. | Treatment approaches for COVID-19: a critical review | |
| US11471448B2 (en) | Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia | |
| EA050436B1 (ru) | Соединения для применения при воспалительных состояниях | |
| Cole | Baloxavir marboxil | |
| WO2023192779A2 (en) | Combined prevention and treatment of patients with respiratory diseases caused by rna viral infections | |
| Hoque | Literature review of prospective drugs for COVID-19 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220825 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250206 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250224 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250606 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250609 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250619 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250619 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250819 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250903 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251028 |